Archit Devarajan

Doctoral Student @NYUniversity | BS-MS (Bio.) @iiserbhopal ('18-'23) | iGEM '20, '21

[Siddhesh Kamat @KamatLab_IISER]

New paper from our lab @IISERPune led by @karthikgs24 & @amolm04, helped by @the_dope_drug, @ArchitDevarajan & Anisha, on developing a bifunctional lipid probe & chemical proteomics on mapping protein ligands for MAG lipids. @Hari_Chakrapani @CommsChem

https://t.co/9s9jKRLflX

[Archit Devarajan @ArchitDevarajan]

Do check it out!!

[Siddhesh Kamat @KamatLab_IISER]

A new paper on @ArnabChaks & @ArchitDevarajan’s collaborative work from our lab @IISERPune, with help from @Kundan703 & Rohith is now online @BiochemistryACS.

https://t.co/oD18nbsC7k

[Siddhesh Kamat @KamatLab_IISER]

Do check out a new preprint from the lab @IISERPune on the bioinformatics analysis and biochemical characterization of ABHD12. Nice work spearheaded by @ArnabChaks & @ArchitDevarajan, with help from @Kundan703 & Rohith.

https://t.co/6HbYT9ht75

[Siddhesh Kamat @KamatLab_IISER]

A new preprint from the lab @IISERPune describing use of chemoproteomics platforms in identifying hitherto unknown MAG protein ligands via MAG probes. Nice work by @karthikgs24, @amolm04, @the_dope_drug, @ArchitDevarajan in collab. with @Hari_Chakrapani. https://t.co/tAg7gszj59

[Archit Devarajan @ArchitDevarajan]

Super grateful to @cardona_lab and @zisanurrahman for allowing me to contribute to this work!

[Archit Devarajan @ArchitDevarajan]

The work that I contributed to as a Mitacs Research Intern is now out in @CellReports!! We report the development of a CRISPRi-seq-based technique for chemical-genetic profiling of antimicrobials and identify a novel inhibitor of the essential enzyme peptidyl-tRNA hydrolase.

[Cell Reports @CellReports]

Rationally designed pooled CRISPRi-seq uncovers an inhibitor of bacterial peptidyl-tRNA hydrolase https://t.co/Quceqs1dPY

[Archit Devarajan @ArchitDevarajan]

Heartiest Congratulations @KamatLab_IISER!!! Extremely proud to be a lab alumnus!!

[Infosys Prize @InfosysPrize]

#InfosysPrize2024 in Life Sciences is awarded to Prof. Siddhesh Kamat, @KamatLab_IISER, of @IISERPune for his discoveries concerning bioactive lipids and their receptors, and their metabolic and signaling pathways. His research using advanced methods to understand the function of lipids, a key component of cells, has important implications for understanding the role of these molecules in a range of cellular functions and human diseases.

[Sigma-Aldrich @SigmaAldrich]

It’s just a tiny bottle.. It probably doesn’t smell that bad
Tiny Bottle:

[Siddhesh Kamat @KamatLab_IISER]

Today was @ArchitDevarajan & @ChaitanyaKatka4’s last day in lab @IISERPune. Both have been wonderful & very productive researchers over the past year & now move on to their PhD’s. Looking forward to exciting science from them. (Pic from their farewell lunch today).

[Archit Devarajan @ArchitDevarajan]

Thank you @cardona_lab, @zisanurrahman and all Cardona Lab Members for a memorable training opportunity full of learning!

[Silvia Cardona @cardona_lab]

📣new from our lab: essential antibacterial targets served in a single test tube! Thanks to the work of
@zisanurrahman @J_Novomisky @ArchitDevarajan in collaboration with @UIC_BioS Yuri Polikanov and Egor Syroegin
#CRISPRi #antibiotics #burkholderia #AMR

[Archit Devarajan @ArchitDevarajan]

@KamatLab_IISER @IISERPune @ChaitanyaKatka4 @haridas_sreedev Congratulations!!

[Archit Devarajan @ArchitDevarajan]

My review article has been featured on front cover of the January 2024 issue of @ACSSynBio!

Link to the article:
https://t.co/k10mY2AGK5

@ACS4Authors #MyACSCover

[Archit Devarajan @ArchitDevarajan]

@Abhi_IISERPune Thank you!

[Archit Devarajan @ArchitDevarajan]

Excited to share my review article on optical-control of #CRISPR-Cas9 and Cre recombinase for gene editing! I talk about the strategies in detail, summarize key challenges & discuss the therapeutic promise of optical-control.

https://t.co/k10mY2AGK5

@iiserbhopal @ACSSynBio

[Archit Devarajan @ArchitDevarajan]

@the_dope_drug Thank you!

[Archit Devarajan @ArchitDevarajan]

@KoladeAdebowal1 @iiserbhopal @ACSSynBio Thank you Kolade!

[CRISPR Therapeutics @CRISPRTX]

#Breaking: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease. Learn more: https://t.co/5U9n8WnoV6

[David R. Liu @davidrliu]

Another major milestone towards not being beholden to the misspellings in our DNA. Congratulations to @CRISPRTX, @VertexPharma, the many scientists and doctors who laid the intellectual foundations for this work, and the patients who will benefit from it. 🍻

[Wei Zhao @zhaoweiasu]

In vivo base editing works in humans!
Congratulations to @KomorLab, @NicoleGaudelli, and @davidrliu for advancing gene editing science and inventing base editing technology!
Great work by both the @BeamTx team and the Verve team to make it happen! @skathire and @ambellinger 👏🎉

[David R. Liu @davidrliu]

In a major milestone for science, for medicine, and for patients, the world’s first CRISPR drug has been approved in the UK.
“A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over after a rigorous assessment of its safety, quality and effectiveness.”
Congratulations to the many scientists, doctors, patients, and industry leaders who made this development possible.🍻
https://t.co/pUL956YsG3